# Seock-Ah Im

Source: https://onco.cc/people/im-seock-ah/  
OnCo record `im-seock-ah` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led MONALEESA-7, which proved a CDK4/6 inhibitor extends survival in premenopausal breast cancer, and steers Korea's breast cancer trial network.

## Summary

Seock-Ah Im is Professor of Internal Medicine at Seoul National University Hospital, specialising in breast medical oncology. She led MONALEESA-7, the trial that proved the CDK4/6 inhibitor ribociclib with endocrine therapy extends survival in premenopausal women with HR-positive, HER2-negative breast cancer, and steers Korea's breast cancer trial network. She is a principal investigator across the ribociclib, palbociclib and antibody-drug conjugate programmes in breast cancer, including triple-negative disease. Her publications include the MONALEESA-7 report on ribociclib plus endocrine therapy, and her interests are CDK4/6 inhibitors, premenopausal breast cancer and antibody-drug conjugates.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Internal Medicine; breast medical oncology
- Specialisms: Breast cancer; CDK4/6 inhibitors; Premenopausal breast cancer; Antibody-drug conjugates

## Sources

- Seoul National University Hospital: https://www.snuh.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Im%20SA%5BAuthor%5D%20Seoul%20National%20University%20breast%20cancer

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/), [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/)
- drugs: [Palbociclib](https://onco.cc/drugs/palbociclib/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- institutions: [Seoul National University Hospital](https://onco.cc/institutions/snuh/)
- key papers: [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/), [DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer](https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/), [TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival](https://onco.cc/key-papers/paper-tropion-breast01-jco-2024/)

---
JSON: https://onco.cc/api/v1/entities/im-seock-ah.json